| FORM 1449* INFORMATION DISCLOSURE STATEMENT | Docket Number:<br>09124.0117US01 | Application Number:<br>09/654,276 |  |  |
|---|----------------------------------|-----------------------------------|--|--|
| IN AN APPLICATION                           | Applicant: Cohen et al.          |                                   |  |  |
| (Use several sheets if necessary)           | Filing Date: September 25, 2006  | Group Art Unit: 1633              |  |  |

|  |   | U.S  | S. PATENT DOCUMEN   | rs                                |                     |                               |  |
|--|---|--|---|-----------------------------------|---------------------|-------------------------------|--|
| EXAMINER<br>INITIAL  | DOCUMENT NO.  | DATE   | NAME  | CLASS                             | SUBCLASS            | FILING DATE<br>IF APPROPRIATE |  |
|  |   |  |   |                                   |                     |                               |  |
|  |   | FORE   | IGN PATENT DOCUM  | ENTS                              |                     | ·                             |  |
|  | DOCUMENT NO.  | DATE   | COUNTRY   | CLASS                             | SUBCLASS            | TRANSLATION                   |  |
|  |   |  |   |                                   |                     |                               |  |
| · · · · · · · · · · · · · · · · · · ·  |   | -  |   |                                   |                     |                               |  |
| <del></del>  | OTUER   | OCUMENTS   | (Including Author, Title, D                               | Nata Danis and I                  | ) E )               |                               |  |
|  |   |  | <del></del>   | Pate, Pertinent i                 | ages, etc.)         |                               |  |
| AW  Horrigan et al., 1996, Circulation, 94(8):1927-1933  "Coronary Heart Disease/Myocardial Infarction: Red Growth Factor After Temporary Coronary Occlusion |   |  |   |                                   |                     | y Basic Fibroblast            |  |
|  | •   |  | Molecular Medicine, 6(2):<br>Embryonic Stem Cells into    |                                   | lies Comprising the | Three Embryonic Germ          |  |
|  | Rowley et a   | Rowley et al., 1999, Biomaterials, 20:45-53  |   |                                   |                     |                               |  |
|  | "Alginate hydrogels as synthetic extracellular matrix material" |  |   |                                   |                     |                               |  |
|  | 1   | Thomson et al., 1998, Science, 282:1145-1147  "Embryonic Stem Cell Lines Derived from Human Blastocysts" |   |                                   |                     |                               |  |
|  | 1   |  | ntion, 100(Suppl. II):II-247                              |                                   | ged Heart Function  | l <sup>1</sup>                |  |
|  |   | <del> </del>   | ntiation, 48:173-182                                      | -                                 |                     |                               |  |
| $\downarrow$   | "Pluripoten   | t mouse embryo   | nic stem cells are able to d<br>cholinergic agents and Ca | ifferentiate into 2+ channel bloc | cardiomyocytes ex   | pressing chronotropic         |  |

23552
PATENT TRADEMARK OFFICE

|          | - $0.110$    |                 |     |     | ,  |  |
|----------|--------------|-----------------|-----|-----|----|--|
| EXAMINER | W.W.         | DATE CONSIDERED | 10/ | 27/ | 06 |  |
|          | <del>-</del> |                 |     |     |    |  |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.